283 related articles for article (PubMed ID: 36965522)
1. Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective.
Luo L; Chang Y; Sheng L
Life Sci; 2023 May; 321():121614. PubMed ID: 36965522
[TBL] [Abstract][Full Text] [Related]
2. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).
Ji Y; Yin Y; Li Z; Zhang W
Nutrients; 2019 Jul; 11(8):. PubMed ID: 31349604
[TBL] [Abstract][Full Text] [Related]
3. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
Chu H; Duan Y; Yang L; Schnabl B
Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
[TBL] [Abstract][Full Text] [Related]
4. The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention.
Yu SY; Xu L
J Appl Microbiol; 2021 Aug; 131(2):564-582. PubMed ID: 33411984
[TBL] [Abstract][Full Text] [Related]
5. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis.
Han H; Jiang Y; Wang M; Melaku M; Liu L; Zhao Y; Everaert N; Yi B; Zhang H
Crit Rev Food Sci Nutr; 2023; 63(12):1689-1706. PubMed ID: 34404276
[TBL] [Abstract][Full Text] [Related]
6. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
7. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
8. Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease.
Park E; Jeong JJ; Won SM; Sharma SP; Gebru YA; Ganesan R; Gupta H; Suk KT; Kim DJ
Cells; 2021 Oct; 10(10):. PubMed ID: 34685614
[TBL] [Abstract][Full Text] [Related]
9. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
Albillos A; de Gottardi A; Rescigno M
J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
[TBL] [Abstract][Full Text] [Related]
10. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.
Aragonès G; González-García S; Aguilar C; Richart C; Auguet T
Biomed Res Int; 2019; 2019():8507583. PubMed ID: 30719448
[TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet.
Mokhtari Z; Gibson DL; Hekmatdoost A
Adv Nutr; 2017 Mar; 8(2):240-252. PubMed ID: 28298269
[TBL] [Abstract][Full Text] [Related]
12. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications.
Fang J; Yu CH; Li XJ; Yao JM; Fang ZY; Yoon SH; Yu WY
Front Cell Infect Microbiol; 2022; 12():997018. PubMed ID: 36425787
[TBL] [Abstract][Full Text] [Related]
13. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications.
Chen J; Vitetta L
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32717871
[TBL] [Abstract][Full Text] [Related]
14. Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota.
Ohtani N; Hara E
Cancer Sci; 2021 Nov; 112(11):4433-4443. PubMed ID: 34533882
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Potential of Natural Plants Against Non-Alcoholic Fatty Liver Disease: Targeting the Interplay Between Gut Microbiota and Bile Acids.
Sun Q; Xin X; An Z; Hu Y; Feng Q
Front Cell Infect Microbiol; 2022; 12():854879. PubMed ID: 35356532
[TBL] [Abstract][Full Text] [Related]
16. Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?
Villard A; Boursier J; Andriantsitohaina R
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G485-G495. PubMed ID: 33471632
[TBL] [Abstract][Full Text] [Related]
17. Diet, Gut Microbiota and Non-Alcoholic Fatty Liver Disease: Three Parts of the Same Axis.
Quesada-Vázquez S; Aragonès G; Del Bas JM; Escoté X
Cells; 2020 Jan; 9(1):. PubMed ID: 31936799
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota and bile acids partially mediate the improvement of fibroblast growth factor 21 on methionine-choline-deficient diet-induced non-alcoholic fatty liver disease mice.
Lin D; Sun Q; Liu Z; Pan J; Zhu J; Wang S; Jia S; Zheng M; Li X; Gong F
Free Radic Biol Med; 2023 Feb; 195():199-218. PubMed ID: 36586452
[TBL] [Abstract][Full Text] [Related]
20. Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease.
Dongoran RA; Tu FC; Liu CH
Tzu Chi Med J; 2023; 35(4):290-299. PubMed ID: 38035056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]